Disease relevance of Mertiatide

• BACKGROUND: Renal scintigraphy with radiolabeled pentetic acid (diethylenetriamine pentaacetic acid [DTPA]) or, more recently, mertiatide (mercaptoacetyltriglycine [MAG3]), with or without captopril challenge, is widely recommended as a diagnostic test for renal artery stenosis [1].
• METHODS: From a large data basis, we found retrospectively only 29 children (10 below and 19 above two years of age at first examination) having had at least two Tc-99m mertiatide (Tc-99m MAG3) renographic explorations for various urological diseases, with a decrease of split function of at least 5% between the two examinations [2].

High impact information on Mertiatide

• OBJECTIVES: To address (1) whether the diagnostic accuracy has been improved by the use of captopril and the introduction of mertiatide and (2) whether a renal scan that shows abnormalities is a useful criterion to select patients for renal arteriography [1].
• A new renal imaging agent, technetium-99m mercaptoacetyltriglycine (MAG3, mertiatide), is currently undergoing clinical trials [3].
• Twenty-eight of the 50 substandard products (56%) involved macroaggregated albumin with the remainder divided among in vitro red blood cells, exametazime, disofenin, sestamibi, mertiatide and sulfur colloid [4].

Analytical, diagnostic and therapeutic context of Mertiatide

• CONCLUSIONS: The diagnostic accuracy of renal scintigraphy has not been improved by the introduction of mertiatide or by the use of captopril [1].

References